[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Noom Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":5},"100640329",false,"NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","FLOURISH","Inclusion Criteria:\n\n* Speaks English\n* Community-dwelling, community-living status\n* Able to ambulate independently, with or without aids or devices\n* Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities\n* Provides informed consent for study participation\n* Commitment and willingness to participate, as assessed by completion of decisional balance exercise\n* Program-specific eligibility:\n* Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.\n* Noom Weight only: Individual who is not interested in medication\n* Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier\n\nExclusion Criteria:\n\n* Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)\n* GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)\n* Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program\n* Previous or planned (during the 12-month study) bariatric surgery\n* Active eating disorder\n* Active cancer\n* Type 1 diabetes or current Insulin use\n* Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)\n* Depression screen results in a PHQ-8 score of 20 or greater.\n\nAll medicated arms and Noom Weight arms (only):\n\n\\- Purchased more than the base Noom program offered for participant's specific arm\n\nGLP-1 Medication Arms Only:\n\n* GLP-1 agonist use is contraindicated (per program criteria) in members with:\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)\n* Personal history of Pancreatitis","ALL","18 Years","64 Years",{"count":20,"type":21},2310,"ESTIMATED","OBSERVATIONAL","This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.\n\nFLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).\n\nTHRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.\n\nParticipants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.",[25,26,27,28,29],"Obesity & Overweight","Weight Loss","Preventative Health","Body Weight","Cardiovascular Disease Risk Factor",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"GLP-1","Microdose","weight","body composition","metabolic","biomarkers","longevity","glucagon-like peptide-1","semaglutide","tirzepatide","microdosing","digital health","weight loss","behavioral health","real world evidence","NOT_YET_RECRUITING","2026-05-08",{"date":49,"type":50},"2026-05-15","ACTUAL",{"date":52,"type":21},"2026-04-30",{"date":54,"type":21},"2029-05",{"name":56,"class":57},"Noom Inc.","INDUSTRY",""]